Advertisement

Topics

Nanobiotix Revenue for the 2nd Quarter of 2018

13:25 EDT 12 Jul 2018 | FinanzNachrichten

Regulatory News: NANOBIOTIX (Paris:NANO)(Euronext: NANO ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer (the "Company"), announ...

Original Article: Nanobiotix Revenue for the 2nd Quarter of 2018

NEXT ARTICLE

More From BioPortfolio on "Nanobiotix Revenue for the 2nd Quarter of 2018"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...